Why is the integration of clinical trials into STOP-HCV so important?
Clinical data and real world patient outcomes are vital to the success of the STOP-HCV project. Information and samples collected from patients undergoing current treatment regimes using new therapies, will provide invaluable information to enable patient stratification and improved clinical outcome.
- STOP-HCV investigators (Prof. Graham Cooke, Chief Investigator and Prof. Eleanor Barnes) have recently secured two awards which will enable the consortium to extend its activities to Vietnam in S.E Asia, where patients are most commonly infected with HCV genotype-6, the most genetically diverse HCV genotype. STOP-HCV will generate host and viral genomic data in collaboration with investigators at OUCRU in Ho Chi Minh City.
- Funding from the NIHR Efficacy and Mechanism Evaluation programme allowed STOP-HCV investigators to undertake a clinical study to look at stratification within short-course, all-oral direct-acting antiviral HCV treatment regimes, for Gt1 HCV infected patients with mild liver disease. Recruitment into the study - STOPHCV1- began in late February 2016.
- In 2014 one of the consortiums industrial partners, Gilead Sciences, undertook a Phase 3 randomised trial to assess the effects of sofosbuvir treatment in patients predominantly with gt3 chronic HCV infection. This study was run in close collaboration with STOP-HCV and samples from these patients are being used for downstream analyses within the STOP-HCV project.
Further information regarding clinical trials in the area of Hepatitis C can be found on the NHS website.
HCV-Trials.com is a regularly updated website with all the most recent clinical trial data in HCV infection